Mark A. Kryah serves as the Executive Director and Program Team Leader at Ultragenyx Pharmaceutical Inc., where he plays a pivotal role in steering the global development of a late-stage asset within Lilly's Immunology pipeline. With over 20 years of experience in biopharmaceuticals, Mark has...
Mark A. Kryah serves as the Executive Director and Program Team Leader at Ultragenyx Pharmaceutical Inc., where he plays a pivotal role in steering the global development of a late-stage asset within Lilly's Immunology pipeline. With over 20 years of experience in biopharmaceuticals, Mark has honed his expertise in global product management and has successfully navigated the complexities of both early and late-phase development. His extensive background encompasses a wide range of therapeutic areas, allowing him to lead projects that not only meet regulatory standards but also address critical patient needs across multiple indications.
At Ultragenyx, Mark is known for his adept situational leadership, which enables him to foster strong cross-functional collaborations among diverse teams. His ability to build and maintain robust alliances has been instrumental in driving product registrations and ensuring compliance with FDA regulations. Mark’s proficiency in change control and computer system validation further enhances his capacity to manage operational complexities in a dynamic environment.
Currently, he is focused on leveraging his global marketing acumen to position Ultragenyx as a leader in the biopharmaceutical landscape. His commitment to excellence is evident in his strategic approach to project management, where he emphasizes the importance of GMP practices and effective communication. With a keen understanding of the intricacies of biotechnology, Mark Kryah continues to make significant contributions to the advancement of innovative therapies, ultimately improving patient outcomes worldwide.
